SB-649868
id:
sb-649868-185-1886397
title:
SB-649868
text:
SB-649868 is a dual orexin receptor antagonist that was being developed by GlaxoSmithKline as a treatment for insomnia. A phase I clinical trial evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects. In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency. The subsequent phase II study added a 60 mg dose and observed dose-dependent sleep promotion. The compound no
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/SB-649868
date created:
2006-02-07T03:40:09Z
date modified:
2024-09-07T15:20:26Z
main entity:
{"identifier":"Q7388914","url":"https://www.wikidata.org/entity/Q7388914"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/d/d7/SB-649%2C868.svg","width":512,"height":395}
fields total:
13
integrity:
16